SCHEMBL3096402

SCHEMBL3096402

CC1(C)CC=C(c2cc(S(N)(=O)=O)ccc2C(N)=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.52
IKBKB O14920 8/20 0.36
CHUK O15111 6/20 0.36
IKBKE Q14164 1/20 0.36
CA2 P00918 2/20 0.35
MAPK12 P53778 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALDH2 P05091 1/20 0.34
ALDH1A3 P47895 1/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090373 0.90 CSF1R (0.50) CSF1RIKBKBCHUKTBK1ALDH1A1
SCHEMBL3096078 0.84 CSF1R (0.41) CSF1R
SCHEMBL3096408 0.83 CSF1R (0.51) CSF1RCA2TBK1ALDH1A1POLB
SCHEMBL3083166 0.82 CSF1R (0.52) CSF1RTBK1
SCHEMBL3092556 0.81 DGAT1 (0.41) CSF1RTBK1
SCHEMBL3090219 0.81 CSF1R (0.55) CSF1R
SCHEMBL4193207 0.80 CSF1R (0.46) CSF1RTBK1
SCHEMBL3084793 0.79 CSF1R (0.39) CSF1RTBK1
SCHEMBL3089868 0.78 CSF1R (0.50) CSF1RTBK1
SCHEMBL3084355 0.78 CSF1R (0.50) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885IKBKB 362/4885CHUK 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.